Business Description
Eupraxia Pharmaceuticals Inc
NAICS : 541714
SIC : 3741
ISIN : CA29842P1053
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.76 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | -0.37 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -113.8 | |||||
3-Year EPS without NRI Growth Rate | -68.8 | |||||
3-Year FCF Growth Rate | -230.3 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 69.5 | |||||
9-Day RSI | 62.88 | |||||
14-Day RSI | 54.48 | |||||
6-1 Month Momentum % | -30.82 | |||||
12-1 Month Momentum % | -45.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.95 | |||||
Quick Ratio | 1.95 | |||||
Cash Ratio | 1.94 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.5 | |||||
Shareholder Yield % | -23.92 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -270.09 | |||||
ROA % | -110.72 | |||||
ROIC % | -290.58 | |||||
ROC (Joel Greenblatt) % | -6043.45 | |||||
ROCE % | -306.49 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 5.3 | |||||
Price-to-Tangible-Book | 5.5 | |||||
EV-to-EBIT | -3.06 | |||||
EV-to-EBITDA | -3.08 | |||||
EV-to-FCF | -3.48 | |||||
Price-to-Net-Current-Asset-Value | 5.58 | |||||
Price-to-Net-Cash | 5.73 | |||||
Earnings Yield (Greenblatt) % | -32.69 | |||||
FCF Yield % | -20.7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Eupraxia Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | |||
EPS (TTM) (C$) | -1.418 | ||
Beta | 1.17 | ||
Volatility % | 63.97 | ||
14-Day RSI | 54.48 | ||
14-Day ATR (C$) | 0.13896 | ||
20-Day SMA (C$) | 3.901 | ||
12-1 Month Momentum % | -45.03 | ||
52-Week Range (C$) | 3.44 - 9.1 | ||
Shares Outstanding (Mil) | 35.62 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Eupraxia Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Eupraxia Pharmaceuticals Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
Eupraxia Pharmaceuticals Inc Frequently Asked Questions
What is Eupraxia Pharmaceuticals Inc(TSX:EPRX)'s stock price today?
When is next earnings date of Eupraxia Pharmaceuticals Inc(TSX:EPRX)?
Does Eupraxia Pharmaceuticals Inc(TSX:EPRX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |